| Literature DB >> 2931206 |
D B Thomas, L Noonan, A Whitehead.
Abstract
The preliminary results of a study of the incidence of breast cancer in relation to use of depot-medroxyprogesterone acetate (DMPA) are presented. The findings are based on data from three participating centres in Thailand, and one each in Kenya and Mexico. A relative risk for breast cancer of 0.7 was observed in women who had ever used DMPA; this was not statistically significant. Although no consistent decrease in risk with duration of use was observed, the lowest relative risk (0.5) was observed in women who had used DMPA for three or more years. These findings are based on small numbers and must be considered preliminary. However, they provide no evidence that DMPA increases the risk of breast cancer, and suggest that it may exert a protective effect, particularly in long-term users.Entities:
Keywords: Africa; Africa South Of The Sahara; Americas; Asia; Breast Cancer; Cancer; Central America; Contraception; Contraceptive Agents, Female--side effects; Contraceptive Agents, Progestin--side effects; Contraceptive Agents--side effects; Depo-provera--side effects; Developed Countries; Developing Countries; Diseases; Eastern Africa; English Speaking Africa; Family Planning; Incidence; Kenya; Latin America; Measurement; Medroxyprogesterone Acetate--side effects; Mexico; Neoplasms; North America; Research Methodology; Southeastern Asia; Thailand
Mesh：
Substances：
Year: 1985 PMID： 2931206 PMCID： PMC2536420
Source DB: PubMed Journal: Bull World Health Organ ISSN： 0042-9686 Impact factor: 9.408